Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 8/20 | 0.57 |
| ▸ | KDM5C | P41229 | 7/20 | 0.57 |
| ▸ | KDM4A | O75164 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | KDM5B | Q9UGL1 | 5/20 | 0.57 |
| ▸ | KDM6B | O15054 | 4/20 | 0.57 |
| ▸ | KDM2A | Q9Y2K7 | 4/20 | 0.57 |
| ▸ | KDM3A | Q9Y4C1 | 4/20 | 0.57 |
| ▸ | KDM5A | P29375 | 3/20 | 0.57 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.57 |
| ▸ | TET3 | O43151 | 1/20 | 0.57 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | ASPH | Q12797 | 1/20 | 0.57 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.57 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.57 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.57 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.57 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7670706 | 0.84 | KDM4C (0.57) | KDM4CKDM5CKDM4AKDM4EKDM5B | |
| SCHEMBL845767 | 0.82 | KDM4C (0.55) | KDM4CKDM5CKDM4AKDM4EKDM5B | |
| SCHEMBL1647272 | 0.82 | CYP1A2 (0.61) | KDM4CKDM5CKDM4AKDM4EKDM5B | |
| SCHEMBL8594535 | 0.82 | CYP1A2 (0.47) | KDM4CKDM5CKDM4AKDM4EKDM5B | |
| SCHEMBL31191238 | 0.82 | KDM4C (0.55) | KDM4CKDM5CKDM4AKDM4EKDM5B | |
| SCHEMBL24690842 | 0.82 | PKM (0.46) | KDM4CKDM5CKDM4AKDM4EKDM5B | |
| SCHEMBL30607268 | 0.82 | CYP1A2 (0.47) | KDM4CKDM5CKDM4AKDM4EKDM5B | |
| SCHEMBL12252467 | 0.82 | GABRP (0.58) | KDM4CKDM5CKDM4AKDM4EKDM5B | |
| SCHEMBL30560163 | 0.82 | KDM4C (0.55) | KDM4CKDM5CKDM4AKDM4EKDM5B | |
| SCHEMBL28331934 | 0.82 | KDM4C (0.55) | KDM4CKDM5CKDM4AKDM4EKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704830-A2 | MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF | Septerna, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024226914-A2 | MRGPRX2 ANTAGONISTS AND METHODS OF USE THEREOF | SEPTERNA, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| CN-118251239-A | Antibody-drug conjugates | MC SAF公司 | 2024-06-25 | — | — | CN | disclosed |
| EP-4110405-A1 | ANTI-CD56 ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THERAPY | MCSAF INSIDE ONOCOLOGY (FR) | 2023-01-04 | — | — | EP | disclosed |
| CN-115515642-A | anti-CD 56 antibody-drug conjugates and their use in therapy | 麦克萨夫内部肿瘤公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-114173825-A | Antibody-drug conjugates and their use in therapy | MCSAF公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2021064332-A1 | ANTI-CD30-DRUG CONJUGATES AND THEIR USE IN THERAPY | MC SAF (FR) | 2021-04-08 | — | — | WO | disclosed |
| CN-107922426-B | Tetrahydrooxepin pyridine compound | 安斯泰来制药株式会社 | 2021-03-26 | — | — | CN | disclosed |
| WO-2020234541-A1 | ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THERAPY | MC SAF (FR) | 2020-11-26 | — | — | WO | disclosed |
| CN-107074807-A | Compositions and methods for inhibiting histone demethylase | 吉利德科学公司 | 2017-08-18 | — | — | CN | disclosed |
| US-20110263564-A1 | PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| EP-2350051-A1 | PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010056549-A1 | PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-7674795-B2 | Fluorene derivatives, composition containing said derivatives and the use thereof | AVENTIS PHARMA SA (FR) | 2010-03-09 | — | — | US | disclosed |
| US-20080153837-A1 | Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-06-26 | — | — | US | disclosed |
| EP-0533130-A1 | 2-Hydroxymethylpyridines, the corresponding pyridine-N-oxides and derivatives thereof, process for their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263564-A1 | PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT6 | KDM4C 1645/4885KDM5C 1023/4885KDM4A 1420/4885 |
| US-20080153837-A1 | Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof | HSP90B1, HSP90AB1, HSP90AA1 | KDM4C 4322/4885KDM5C 4142/4885KDM4A 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.